Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Valeant acquires U.S. Targretin rights from Eisai
April 2013
SHARING OPTIONS:

WOODCLIFF LAKE, N.J.Valeant Pharmaceuticals International Inc. has acquired U.S. rights for Targretin (bexarotene) capsules and Targretin (bexarotene) gel 1% from Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co. Ltd., for $65 million. The terms of the acquisition also include potential contingent payments if certain milestones are met. In conjunction with the transaction, Eisai has transferred the New Drug Application for Targretin to Valeant, which will assume responsibility for all associated regulatory duties for the drug in the United States. Eisai will retain the rights to Targretin outside of the United States. Targretin capsules are a dermatological therapy used to treat skin problems that arise from a disease known as cutaneous T-cell lymphoma when at least one previous systemic therapy has not worked.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.